Replimune Group (7R8) Price & Analysis

0 Followers

7R8 Stock Chart & Stats

€12.86

-€1.68(-22.60%)

At close: Jul 28 4:00 PM EDT

€12.86

-€1.68(-22.60%)

Day’s Range― - ―

52-Week Range€1.43 - €13.83

Previous CloseN/A

Volume0.00

Average Volume (3M)121.00

Market Cap

€1.06B

Enterprise Value€988.94

Total Cash (Recent Filing)€195.33M

Total Debt (Recent Filing)€111.97M

Price to Earnings (P/E)―

Beta0.73

Next Earnings

Oct 29, 2026

EPS Estimate

-0.68

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.15

Shares Outstanding94,219,635

10 Day Avg. Volume10

30 Day Avg. Volume121

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)4.27

Price to Sales (P/S)0.00

P/FCF Ratio-2.49

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€16.60

Price Target Upside29.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-2.42

Revenue Forecast (FY)€36.85M

Bulls Say, Bears Say

Bulls Say

Regulatory ApprovalAccelerated approval gives Replimune its first commercial oncology opportunity and validates the clinical potential of its oncolytic immunotherapy approach. It also creates a pathway to generate product revenue while confirmatory testing proceeds, strengthening the company’s strategic position in a difficult-to-treat melanoma setting.

Proprietary PlatformA proprietary platform spanning multiple engineered virus candidates and tumor types can create development leverage beyond a single asset. Replimune’s ability to test RP1, RP2 and RP3 with checkpoint inhibitors supports a broader pipeline and may improve the durability of its competitive position if clinical validation continues.

Modest LeverageRelatively modest debt compared with assets provides some balance-sheet flexibility as Replimune advances development and commercialization. Lower leverage can reduce fixed financial obligations and leave management more capacity to direct available capital toward clinical programs, regulatory commitments and market launch activities.

Bears Say

Pre-revenue LossesThe company remains dependent on successful development and commercialization rather than an established recurring revenue base. Widening losses show that operating expenses currently exceed any income contribution, limiting operating leverage and leaving future financial performance highly dependent on product uptake and clinical execution.

Heavy Cash BurnSustained cash outflows materially increase the funding required to support clinical trials, regulatory work and commercialization. Because free cash flow has not stabilized, Replimune may need additional financing before internally generated cash can fund operations, increasing exposure to capital-market access and shareholder dilution.

Equity Erosion And DilutionSharp equity erosion reflects the cumulative effect of operating losses and reduces the capital cushion available to absorb execution setbacks. The expanded share authorization improves financing flexibility but also enables substantial future issuance, creating a durable risk that existing ownership and per-share economic participation will be diluted.

Replimune Group News

Replimune price target raised to $21 from $20 at JPMorgan

JPMorgan raised the firm’s price target on Replimune (REPL) to $21 from $20 and keeps an Overweight rating...

24d ago

REPL

Replimune shareholders approve stock expansion and governance items

Replimune Group ( ($REPL) ) just unveiled an update. On September 15, 2026, Replimune Group, Inc. held its...

2d ago

REPL

Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process

Replimune Group, Inc. (NASDAQ: REPL) and several current or former company leaders have asked a federal court in Massachusetts...

23d ago

REPL

Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop

Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that investors were not told key facts...

28d ago

REPL

Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop

Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that investors were not told key facts...

1M ago

REPL

Replimune reports Q1 EPS (72c), consensus (77c)

“The FDA’s approval of TUDRIQEV is a defining milestone for Replimune (REPL) and, more importantly, for the patients...

1M ago

REPL

Replimune files automatic mixed securities shelf

16:53 EDT Replimune (REPL) files automatic mixed securities shelf Published first on TheFly – the ultimate source for...

1M ago

REPL

Replimune Group Lawsuit Alleges Investors Were Misled Before REPL Stock Drop

Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that the company misled investors about...

1M ago

REPL

Replimune 9.7M share Spot Secondary priced at $12.06

Leerink, JPMorgan and Cantor Fitzgerald are acting as joint book running managers for the offering. The deal priced...

1M ago

REPL

Replimune Raises $150 Million in Equity Offering

Replimune Group ( ($REPL) ) has shared an update. On August 9, 2026, Replimune Group, Inc. entered into...

1M ago

REPL

Replimune Wins FDA Accelerated Approval for TUDRIQEV

Replimune Group ( ($REPL) ) has shared an update. On August 6, 2026, Replimune announced that the U.S....

1M ago

REPL

Replimune price target raised to $20 from $16 at BMO Capital

BMO Capital raised the firm’s price target on Replimune (REPL) to $20 from $16 and keeps an Outperform...

1M ago

REPL

Wedbush upgrades Replimune to Outperform following FDA decision

As previously reported, Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $19, up...

1M ago

REPL

Replimune upgraded to Outperform from Neutral at Wedbush

Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $19, up from $12. Published...

1M ago

REPL

7R8 FAQ

What was Replimune Group Inc’s price range in the past 12 months?

Replimune Group Inc lowest stock price was €1.43 and its highest was €13.83 in the past 12 months.

What is Replimune Group Inc’s market cap?

Replimune Group Inc’s market cap is €1.06B.

When is Replimune Group Inc’s upcoming earnings report date?

Replimune Group Inc’s upcoming earnings report date is Oct 29, 2026 which is in 40 days.

How were Replimune Group Inc’s earnings last quarter?

Replimune Group Inc released its earnings results on Aug 14, 2026. The company reported -€0.62 earnings per share for the quarter, missing the consensus estimate of -€0.598 by -€0.022.

Is Replimune Group Inc overvalued?

According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Replimune Group Inc pay dividends?

Replimune Group Inc does not currently pay dividends.

What is Replimune Group Inc’s EPS estimate?

Replimune Group Inc’s EPS estimate is -0.68.

How many shares outstanding does Replimune Group Inc have?

Replimune Group Inc has 94,219,635 shares outstanding.

What happened to Replimune Group Inc’s price movement after its last earnings report?

Replimune Group Inc reported an EPS of -€0.62 in its last earnings report, missing expectations of -€0.598. Following the earnings report the stock price went up 4.075%.

Which hedge fund is a major shareholder of Replimune Group Inc?

Currently, no hedge funds are holding shares in DE:7R8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Replimune Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-46.23%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Replimune Group Inc

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Replimune Group (7R8) Earnings & Revenues

Historic Earnings Reports

7R8 Stock 12 Month Forecast

Average Price Target

€16.60

▲(29.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","6":"€6","11":"€11","16":"€16","21":"€21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20.81111304,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€20.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.599340162857146,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€16.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.13981594,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.745,13.365470233846153,13.985940467692307,14.606410701538461,15.226880935384614,15.84735116923077,16.467821403076922,17.088291636923074,17.70876187076923,18.329232104615386,18.949702338461538,19.57017257230769,20.190642806153846,{"y":20.81111304,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.745,13.041487704835165,13.33797540967033,13.634463114505495,13.93095081934066,14.227438524175826,14.523926229010991,14.820413933846154,15.11690163868132,15.413389343516485,15.70987704835165,16.006364753186816,16.30285245802198,{"y":16.599340162857146,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.745,12.69844738,12.65189476,12.60534214,12.55878952,12.5122369,12.46568428,12.41913166,12.37257904,12.32602642,12.2794738,12.23292118,12.18636856,{"y":12.13981594,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.336,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.625,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.745,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >